Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria.
Childhood malaria caused by Plasmodium falciparum is often characterized by severe anemia at low parasite burdens; the mechanism(s) responsible for this pathology remain to be defined. We have reported, based on clinical observations and in vitro models, that complement control proteins on erythrocytes such as CR1, the immune adherence receptor specific for C3b, may be reduced in childhood malaria, suggesting a possible role for complement in erythrocyte destruction. Intravascular lysis of iE by P. falciparum leads to release of erythrocyte breakdown products such as hemoglobin and hematin, which have inflammatory properties. In the present article, we demonstrate that in serum and in anticoagulated whole blood, moderate concentrations of hematin activate the alternative pathway of complement and promote deposition of C3 activation and breakdown products on erythrocytes. The degree of C3 fragment deposition is directly correlated with erythrocyte CR1 levels, and erythrocytes opsonized with large amounts of C3dg form rosettes with Raji cells, which express CR2, the C3dg receptor which is expressed on several types of B cells in the spleen. Thus, the reaction mediated by hematin promotes opsonization and possible clearance of the youngest (highest CR1) erythrocytes. A mAb specific for C3b, previously demonstrated to inhibit the alternative pathway of complement, completely blocks the C3 fragment deposition reaction. Use of this mAb in nonhuman primate models of malaria may provide insight into mechanisms of erythrocyte destruction and thus aid in the development of targeted therapies based on inhibiting the alternative pathway of complement.
Pawluczkowycz
Andrew W
AW
Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Lindorfer
Margaret A
MA
Waitumbi
John N
JN
Taylor
Ronald P
RP
D000740:Anemia / Q000097:blood / Q000276:immunology*; D045744:Cell Line, Tumor; D003176:Complement C3 / Q000378:metabolism*; D003170:Complement Pathway, Alternative / Q000276:immunology*; D004912:Erythrocytes / Q000276:immunology / Q000378:metabolism*; D006427:Hemin / Q000502:physiology*; D006801:Humans; D008288:Malaria / Q000097:blood / Q000276:immunology*; D010446:Peptide Fragments / Q000097:blood* / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology; D017463:Receptors, Complement 3b / Q000097:blood / Q000502:physiology; D044967:Serum
C509991:CR1 protein, human; D003176:Complement C3; D010446:Peptide Fragments; D017463:Receptors, Complement 3b; D006427:Hemin